Precision Nanosystems - New tools & New papers

Precision Nanosystems Nanoassemblr
Post publication date: 
Friday, February 5, 2016

Things are happening at Precision NanoSystems Inc. (PNI)
With new NanoAssemblr™ product launches throughout 2016, PNI aims to enable microfluidic-based manufacture of nanoparticles across the entire nanomedicine research and development pipeline, from discovery to GMP manufacture.

The current NanoAssemblr™ Benchtop instrument is designed for rapid nanoparticle candidate development (1.5 mL - 15mL).

PNI will be launching new complementary instruments:

- Small volume discovery instrument
- Large volume pre-clinical development instrument
- GMP instrument

Here below are two papers recently issued.

Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies

Dan Peer Group - Tel Aviv University

"Despite progress in systemic small interfering RNA (siRNA) delivery to the liver and to solid tumors, systemic siRNA delivery to leukocytes remains challenging. The ability to silence gene expression in leukocytes has great potential for identifying drug targets and for RNAi-based therapy for leukocyte diseases."

Article

Designing Liposomal Adjuvants for the Next Generation of Vaccines

Yvonne Perrie Group - Aston University

"Liposomes not only offer the ability to enhance drug delivery, but can effectively act as vaccine delivery systems and adjuvants. Their flexibility in size, charge, bilayer rigidity and composition allow for targeted antigen delivery via a range of administration routes. In the development of liposomal adjuvants, the type of immune response promoted has been linked to their physico-chemical characteristics, with the size and charge of the liposomal particles impacting on liposome biodistribution, exposure in the lymph nodes and recruitment of the innate immune system. [...]"

Article